Bernard I. Dentz

Array ( [id] => 16206901 [patent_doc_number] => 20200239891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => CONTROL OF PLANT PESTS USING RNA MOLECULES [patent_app_type] => utility [patent_app_number] => 16/756298 [patent_app_country] => US [patent_app_date] => 2018-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16756298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19256315 [patent_doc_number] => 12016339 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Control of plant pests using RNA molecules [patent_app_type] => utility [patent_app_number] => 16/756232 [patent_app_country] => US [patent_app_date] => 2018-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32167 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16756232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437093 [patent_doc_number] => 20200354419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 16/761112 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16761112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598369 [patent_doc_number] => 20210024900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => METHODS AND COMPOSITIONS RELATED TO INCREASED ROTAVIRUS PRODUCTION [patent_app_type] => utility [patent_app_number] => 16/761009 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16761009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16028677 [patent_doc_number] => 10676747 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-09 [patent_title] => Methods for improving cognitive function via modulation of quinone reductase 2 [patent_app_type] => utility [patent_app_number] => 16/173959 [patent_app_country] => US [patent_app_date] => 2018-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 25 [patent_no_of_words] => 14218 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16173959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16704598 [patent_doc_number] => 10954519 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression [patent_app_type] => utility [patent_app_number] => 16/167783 [patent_app_country] => US [patent_app_date] => 2018-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44943 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16167783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18558763 [patent_doc_number] => 11723988 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-15 [patent_title] => Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector [patent_app_type] => utility [patent_app_number] => 16/756988 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14761 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16756988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15975737 [patent_doc_number] => 10668170 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-02 [patent_title] => Modified RNAi agents [patent_app_type] => utility [patent_app_number] => 16/165343 [patent_app_country] => US [patent_app_date] => 2018-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30835 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16165343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16703121 [patent_doc_number] => 10953034 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection [patent_app_type] => utility [patent_app_number] => 16/162279 [patent_app_country] => US [patent_app_date] => 2018-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 28 [patent_no_of_words] => 47475 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16162279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13871441 [patent_doc_number] => 20190032061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions [patent_app_type] => utility [patent_app_number] => 16/157726 [patent_app_country] => US [patent_app_date] => 2018-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16157726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16244823 [patent_doc_number] => 10744151 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-08-18 [patent_title] => Micro-RNA profiling, compositions, and methods of treating diseases [patent_app_type] => utility [patent_app_number] => 16/153342 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 11185 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16153342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14043975 [patent_doc_number] => 20190078094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => Aptamer specifically binding to L-Ascorbic acid and use of the same [patent_app_type] => utility [patent_app_number] => 16/148236 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3326 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16148236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16290342 [patent_doc_number] => 10767179 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => MicroRNA composition for the treatment of neuroblastoma [patent_app_type] => utility [patent_app_number] => 16/148466 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 11987 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16148466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16223062 [patent_doc_number] => 20200248178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 16/649565 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16157235 [patent_doc_number] => 20200216850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => SPLICE INHIBITING OLIGONUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 16/648822 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27760 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18701589 [patent_doc_number] => 11788088 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => CRISPR/Cas system and method for genome editing and modulating transcription [patent_app_type] => utility [patent_app_number] => 16/650496 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 23 [patent_no_of_words] => 22359 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16650496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16484286 [patent_doc_number] => 20200377887 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASE [patent_app_type] => utility [patent_app_number] => 16/649244 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60638 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13778683 [patent_doc_number] => 20190002880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => DOUBLE-STRANDED OLIGONUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 16/131512 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40807 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16131512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13867353 [patent_doc_number] => 20190030017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => PREDICTING RESPONSE TO ALVOCIDIB BY MITOCHONDRIAL PROFILING [patent_app_type] => utility [patent_app_number] => 16/132270 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18529 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16132270 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132767 [patent_doc_number] => 20190100773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => METABOLICALLY ACTIVATED RECOMBINANT VIRAL VECTORS AND METHODS FOR THEIR PREPARATION AND USE [patent_app_type] => utility [patent_app_number] => 16/130942 [patent_app_country] => US [patent_app_date] => 2018-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20891 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16130942 [rel_patent_id] =>[rel_patent_doc_number] =>)